Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137812 · ClinicalTrials.gov registry record · Phase 3
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
- 20
- Study locations
NCT01137812 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Janssen Research & Development. The registered enrollment target is 756 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT01137812, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Canagliflozin 300 mg
- DRUG Sitagliptin 100 mg
- DRUG Sulphonylurea
Study Locations (20)
California
- - Escondido
- - Fresno
- - Greenbrae
- - La Mesa
- - Laguna Hills
- - Lancaster
- - Long Beach
- - Los Angeles
- - Norwalk
- - Pismo Beach
- - Roseville
- - Spring Valley
- - Walnut Creek
- - Watsonville
Arizona
- - Goodyear
- - Mesa
Colorado
- - Denver
- - Northglenn
Alabama
- - Mobile
Connecticut
- - Milford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01137812
The ClinicalTrials.gov registry entry for NCT01137812 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Metformin is the first listed.
NCT01137812 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT01137812 about?
NCT01137812 is a clinical study titled "The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)". The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
What is the current status of trial NCT01137812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2010-07. Estimated completion is 2012-03.
What conditions does trial NCT01137812 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01137812?
The interventions under investigation include: Metformin (DRUG), Canagliflozin 300 mg (DRUG), Sitagliptin 100 mg (DRUG), Sulphonylurea (DRUG).
Who is sponsoring clinical trial NCT01137812?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01137812 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.